Imlifidase

Name: Imlifidase in Kidney transplantation in highly sensitized patients: Mechanism of action
Published: 2026-09-14T15:39:06-04:00

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Pharmacology

Mechanism of action

1 evidence topic · 1 source

Mechanism of action

“Imlifidase is an IgG-inactivating therapy based on a cysteine protease originating from Streptococcus pyogenes.” (opens the source at this quote in a new tab)
“cleaves IgG-antibodies and inhibits their activity within hours after administration.” (opens the source at this quote in a new tab)